TAIPEI, Taiwan and SAN DIEGO, Dec. 6, 2016 /PRNewswire/ -- Senhwa Biosciences, Inc., a leading company in developing novel small molecule targeted therapy and drugs, announced that it will publish the Phase I results of CX-4945 for the treatment of cholangiocarcinoma in combination with gemcitabine plus cisplatin, during the 2017 Gastrointestinal Cancers Symposium in San Francisco, California, USA organized by the American Society for Clinical Oncology (ASCO).
These clinical trial results show that CX-4945 can be administered safely in combination with these standard-of-care chemotherapy agents, and observed clinical activity suggest an advantage in the combination. This combination will now advance to a randomized phase 2 study in comparison with the standard-of-care treatment.
These results are to be presented as a poster during the symposium, which is held from January 19 to 21, 2017. The abstract will be available online starting on January 17, 2017, and may be found at the following web link at that time: http://meetinglibrary.asco.org/ (Abstract ID: 177218)
About CX-4945
This compound inhibits protein kinase CK2 which was one of the earliest kinases to be discovered and characterized. CK2's role in the control of cell growth and proliferation is undisputed but its complex cellular biology has hampered development as a drug target. Senhwa has focused on exploiting CK2's critical role in DNA damage repair to significantly increase the efficacy of commonly used chemotherapy agents.
About Senhwa Biosciences, Inc.
Senhwa Biosciences identifies and develops innovative therapies that have the potential to fundamentally change the way patients are treated. Our central philosophy is to unearth validated targets or therapies that could significantly improve treatment, but have not yet been properly exploited. As a value-added development company, Senhwa aims to take innovative therapies that could impact the current standard of care and drive them through clinical Proof-of-Concept.
Senhwa has a strong Management Team with proven track records in developing new drugs and targeted agents. Headquartered in Taiwan, but with a vital operational base in San Diego, California, the Senhwa Team is well positioned to oversee the development of their compounds by collaborating with a diverse range of global Investigators and service providers. Clinical trials are ongoing or planned for Australia and the US, and service providers work from their bases in North America, Asia, Australia and Europe. For more information on Senhwa and its programs, please visit www.senhwabio.com.
Advertisement
These clinical trial results show that CX-4945 can be administered safely in combination with these standard-of-care chemotherapy agents, and observed clinical activity suggest an advantage in the combination. This combination will now advance to a randomized phase 2 study in comparison with the standard-of-care treatment.
Advertisement
These results are to be presented as a poster during the symposium, which is held from January 19 to 21, 2017. The abstract will be available online starting on January 17, 2017, and may be found at the following web link at that time: http://meetinglibrary.asco.org/ (Abstract ID: 177218)
About CX-4945
This compound inhibits protein kinase CK2 which was one of the earliest kinases to be discovered and characterized. CK2's role in the control of cell growth and proliferation is undisputed but its complex cellular biology has hampered development as a drug target. Senhwa has focused on exploiting CK2's critical role in DNA damage repair to significantly increase the efficacy of commonly used chemotherapy agents.
About Senhwa Biosciences, Inc.
Senhwa Biosciences identifies and develops innovative therapies that have the potential to fundamentally change the way patients are treated. Our central philosophy is to unearth validated targets or therapies that could significantly improve treatment, but have not yet been properly exploited. As a value-added development company, Senhwa aims to take innovative therapies that could impact the current standard of care and drive them through clinical Proof-of-Concept.
Senhwa has a strong Management Team with proven track records in developing new drugs and targeted agents. Headquartered in Taiwan, but with a vital operational base in San Diego, California, the Senhwa Team is well positioned to oversee the development of their compounds by collaborating with a diverse range of global Investigators and service providers. Clinical trials are ongoing or planned for Australia and the US, and service providers work from their bases in North America, Asia, Australia and Europe. For more information on Senhwa and its programs, please visit www.senhwabio.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/senhwa-cx-4945-phase-i-clinical-trial-results-accepted-for-presentation-at-the-2017-asco-gastrointestinal-cancers-symposium-300373434.html
SOURCE Senhwa Biosciences, Inc.
